NCT06856213
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06856213
Title Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression to First-Line Pembrolizumab Plus Platinum-5FU in Subjects with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. (ERBIOTAX)
Acronym ERBIOTAX
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.